Larimar Therapeutics (LRMR) Net Cash Flow Growth (1y) (2014 - 2025)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Net Cash Flow Growth (1y) (2014 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 349.49% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -55.11% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 172.72% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 53.21% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 47.11% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -100.75% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,371.48% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -104.22% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 99.31% |
| Mar 31, 2025 | -114.50% |
| Dec 31, 2024 | 78.17% |
| Sep 30, 2024 | 104.95% |
| Jun 30, 2024 | -352.33% |
| Mar 31, 2024 | -1.56% |
| Dec 31, 2023 | 79.72% |
| Sep 30, 2023 | -500.63% |
| Jun 30, 2023 | -129.80% |
| Mar 31, 2023 | 1,224.37% |
| Dec 31, 2022 | -4,047.20% |
| Sep 30, 2022 | 51.23% |
| Jun 30, 2022 | -188.73% |
| Mar 31, 2022 | -26.50% |
| Dec 31, 2021 | 95.69% |
| Sep 30, 2021 | -67.09% |
| Jun 30, 2021 | -92.54% |
| Mar 31, 2021 | -4,781.15% |
| Dec 31, 2020 | -635.91% |
| Sep 30, 2020 | -375.38% |